Boston enrols first patient in UAE (uterine artery embolisation) trial:
This article was originally published in Clinica
Boston Scientific's Medi-tech division has enrolled the first patient in a US trial of its minimally invasive uterine artery embolisation (UAE) procedure. The multicentre trial will assess the use of the company's FasTracker325 infusion catheter and Contour-PVA embolic particles as a means of blocking blood flow to the vessels feeding the fibroid. Depriving the fibroid of its blood supply could reduce the symptoms associated with uterine fibroids, says Natick, Massachusetts-based Boston Scientific. Standard treatments for the condition include hysterectomy and myomectomy.